Sutro Biopharma STRO Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Financing Component On Unearned Revenue | $3.41M-45.7% | $6.29M-36.1% | $9.84M— | —— | |
| Materials Supply | $11.71M+581% | $1.72M-58.4% | $4.14M— | —— | |
| Ongoing Performance Related To Unsatisfied Performance Obligations | $75.94M+110% | $36.11M+112% | $17.02M— | —— | |
| Research And Development Services | $2.46M-52.7% | $5.2M-21.0% | $6.58M+162% | $2.51M-5.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Sutro Biopharma break its business down?
- Sutro Biopharma (STRO) reports revenue by product across 4 parts — Financing Component On Unearned Revenue, Materials Supply, Ongoing Performance Related To Unsatisfied Performance Obligations and Research And Development Services. Each is extracted from the segment footnotes and tracked over time.
- Where does Sutro Biopharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Sutro Biopharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
